| Ms Alisa Barnes, PAC | |
|
621 N Main St, Bellevue, ID 83313-5093 | |
| (208) 725-3145 | |
| Not Available |
| Full Name | Ms Alisa Barnes |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 18 Years |
| Location | 621 N Main St, Bellevue, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285797357 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | PA18678 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Family Health Services Corporation | 7012815038 | 42 |
News Archive
Proper laundering and handling are important in achieving and maintaining the hygienically-clean quality of healthcare fabrics and textiles delivered to the point of care, according to a new review that highlights evidence-based strategies to inhibit potentially serious contamination.
Researchers at Signature Genomic Laboratories, which performs diagnostic genetic testing of chromosome abnormalities in individuals with unexplained physical and developmental disabilities, including autism, recently characterized a broad spectrum of developmental and behavior problems in individuals with a DNA imbalance that has been associated with autism.
Putnam Hospital Center in Carmel, NY, is leading by example when it comes to promoting healthy lifestyle choices and encouraging workplace wellness. The CEO Roundtable on Cancer has accredited Putnam Hospital Center with the CEO Cancer Gold Standard recognizing the firm's efforts to reduce the risk of cancer for its employees and covered family members by establishing programs to reduce cancer risk, encouraging early detection through cancer screenings, and ensuring access to quality treatment.
Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.
Parents from lower-income families are less likely to describe their home tap water as safe, say their water has been tested or feel confident in the quality of drinking fountain water at their child's school compared with higher-income peers, a new national poll suggests.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Alisa Barnes, PAC 794 Eastland Dr, Twin Falls, ID 83301-6856 Ph: (208) 737-6718 | Ms Alisa Barnes, PAC 621 N Main St, Bellevue, ID 83313-5093 Ph: (208) 725-3145 |
News Archive
Proper laundering and handling are important in achieving and maintaining the hygienically-clean quality of healthcare fabrics and textiles delivered to the point of care, according to a new review that highlights evidence-based strategies to inhibit potentially serious contamination.
Researchers at Signature Genomic Laboratories, which performs diagnostic genetic testing of chromosome abnormalities in individuals with unexplained physical and developmental disabilities, including autism, recently characterized a broad spectrum of developmental and behavior problems in individuals with a DNA imbalance that has been associated with autism.
Putnam Hospital Center in Carmel, NY, is leading by example when it comes to promoting healthy lifestyle choices and encouraging workplace wellness. The CEO Roundtable on Cancer has accredited Putnam Hospital Center with the CEO Cancer Gold Standard recognizing the firm's efforts to reduce the risk of cancer for its employees and covered family members by establishing programs to reduce cancer risk, encouraging early detection through cancer screenings, and ensuring access to quality treatment.
Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.
Parents from lower-income families are less likely to describe their home tap water as safe, say their water has been tested or feel confident in the quality of drinking fountain water at their child's school compared with higher-income peers, a new national poll suggests.
› Verified 8 days ago
Elizabeth Mullin, Physician Assistant Medicare: Medicare Enrolled Practice Location: 621 N Main St, Bellevue, ID 83313 Phone: 208-725-3145 |